ArticleThe Journal of clinical and aesthetic dermatology2019
Safety and Tolerability of Sarecycline for the Treatment of Acne Vulgaris: Results from a Phase III, Multicenter, Open-Label Study and a Phase I Phototoxicity Study.
Article in The Journal of clinical and aesthetic dermatology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Sarecycline for moderate to severe acne: a promising narrow-spectrum antibacterial drug.Naunyn-Schmiedeberg's archives of pharmacology · 2025Pooled it
- Beyond Isotretinoin: A Narrative Review of Emerging Systemic Therapies for Moderate-to-Severe Acne.Journal of cosmetic dermatology · 2026Review
- Efficacy and Safety of Sarecycline in Chinese Patients with Moderate-to-Severe Acne Vulgaris: Randomized Phase 3 Clinical Trial with Open-Label Follow-Up.Dermatology and therapy · 2025Article
- Plant Phenolics in the Prevention and Therapy of Acne: A Comprehensive Review.Molecules (Basel, Switzerland) · 2024Review
- A Retrospective Review of a Cohort of Patients with Periorificial Dermatitis Treated with Sarecycline.The Journal of clinical and aesthetic dermatology · 2024Article
- Exploring Acne Treatments: From Pathophysiological Mechanisms to Emerging Therapies.International journal of molecular sciences · 2024Review
- Tetracyclines Revisited: Tetracyclines in the Field of Dermatology.Dermatology (Basel, Switzerland) · 2024Review
- Managing common dermatologic needs in transgender and gender-diverse adolescents.Current pediatrics reports · 2024Article
- Article
- Acne Vulgaris-Novel Treatment Options and Factors Affecting Therapy Adherence: A Narrative Review.Journal of clinical medicine · 2022Review
- Review
- Sarecycline Demonstrates Clinical Effectiveness against Staphylococcal Infections and Inflammatory Dermatoses: Evidence for Improving Antibiotic Stewardship in Dermatology.Antibiotics (Basel, Switzerland) · 2022Article
- Sarecycline treatment for acne vulgaris: Rationale for weight-based dosing and limited impact of food intake on clinical efficacy.Dermatologic therapy · 2022Article
- Reduced blood-brain barrier penetration of acne vulgaris antibiotic sarecycline compared to minocycline corresponds with lower lipophilicity.Frontiers in medicine · 2022Article
- The Development of Third-Generation Tetracycline Antibiotics and New Perspectives.Pharmaceutics · 2021Review
- Tetracyclines and photosensitive skin reactions: A narrative review.Dermatologic therapy · 2021Review
- Antibacterial Mechanisms and Efficacy of Sarecycline in Animal Models of Infection and Inflammation.Antibiotics (Basel, Switzerland) · 2021Review
- New Acne Therapies and Updates on Use of Spironolactone and Isotretinoin: A Narrative Review.Dermatology and therapy · 2021Review
- SARECYCLINE AND THE NARROW-SPECTRUM TETRACYCLINE CONCEPT: Currently Available Data and Potential Clinical Relevance in Dermatology.The Journal of clinical and aesthetic dermatology · 2020Review
- Sarecycline: A Review of Preclinical and Clinical Evidence.Clinical, cosmetic and investigational dermatology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
32038757PMC6937166W3005801927What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.